Welcome to our dedicated page for Verastem SEC filings (Ticker: VSTM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Verastem, Inc. filings document a Nasdaq-listed biopharmaceutical company with common stock trading under VSTM and a business focused on RAS/MAPK pathway-driven cancers. Its 8-K reports furnish corporate presentations, financial-result releases, strategic updates, clinical data disclosures, and Regulation FD materials for AVMAPKI FAKZYNJA CO-PACK, RAMP clinical programs, and VS-7375.
The company’s SEC records also cover capital-structure activity, including common stock and pre-funded warrant offerings, and proxy disclosures for board matters, executive compensation, equity awards, and shareholder voting. These filings frame Verastem’s commercialization, pipeline development, governance, financing, and public-company reporting obligations.
JOHNSON JOHN reported acquisition or exercise transactions in this Form 4 filing.
Verastem, Inc. director John Johnson reported receiving a grant of 36,000 restricted stock units (RSUs) of Common Stock at no cash cost as equity compensation. Following this award, he holds 52,666 shares directly.
The RSUs were granted under Verastem's Amended and Restated 2021 Equity Incentive Plan. They vest in twelve substantially equal monthly installments from the end of June 2026 through April 2027, with the final installment vesting before the 2027 Annual Meeting of Stockholders or by May 31, 2027, as long as he continues serving as a director on each vesting date.
Verastem, Inc. reported the results of its 2026 annual stockholder meeting held in Needham, Massachusetts on May 21, 2026. Stockholders elected Class II directors Michael Bailey, Brian Stuglik and Karin Tollefson to serve until the 2029 annual meeting.
Investors also approved the Amended and Restated 2021 Equity Incentive Plan and the Amended and Restated 2018 Employee Stock Purchase Plan, supporting the company’s long-term compensation and employee ownership programs. Stockholders ratified Ernst & Young LLP as independent auditor for the current fiscal year and gave advisory approval to the compensation of the company’s named executive officers.
Foresite Capital Fund VI LP and related reporting persons report beneficial ownership of 3,146,631 shares of Verastem, Inc. common stock, representing 3.6% of the class. The percentage is calculated using 87,873,639 shares outstanding as of May 4, 2026, per the issuer's Form 10-Q.
The filing is an amendment to a Schedule 13G filed jointly by Foresite Capital Fund VI LP, Foresite Capital Management VI LLC and James B. Tananbaum and describes voting and dispositive power attributable through the fund and its general partner.
Verastem, Inc. Schedule 13G/A: Armistice Capital, LLC and Steven Boyd report beneficial ownership of 4,592,000 shares of Verastem common stock, equal to 5.23% of the class as of 03/31/2026. The filing states Armistice Capital, as investment manager to Armistice Capital Master Fund Ltd. (the Master Fund), shares voting and dispositive power over those shares; the Master Fund disclaims beneficial ownership by virtue of the Investment Management Agreement. The statement is a joint filing by Armistice Capital and Steven Boyd and lists shared voting and dispositive power of 4,592,000 shares.
Verastem, Inc. Schedule 13G/A amendment reporting that RTW Investments, LP and Roderick Wong each claim beneficial ownership of 9,018,724 shares of Common Stock, representing 9.99% of the class assuming exercise of Warrants. The filing states the percentage is calculated using 87,835,106 Shares outstanding as of February 27, 2026 and assumes exercise of 2,442,418 Warrants subject to a 9.99% ownership cap on exercise.
The filing explains shared voting and dispositive power over 9,018,724 Shares for both reporting persons, and notes RTW Funds hold the right to receive dividends or sale proceeds, with RTW Master Fund, Ltd. identified as holding over 5% of the reported shares. The statement is signed by Roderick Wong.
Verastem Inc. Schedule 13G/A (Amendment No. 5) reporting that Balyasny Asset Management and affiliated entities may be deemed to beneficially own 1,360,391 shares of Common Stock. The disclosure states this represents approximately 1.55% of the class based on 87,835,106 shares outstanding as of February 27, 2026.
The filing attributes the position to Balyasny Asset Management L.P., BAM GP LLC, Balyasny Asset Management Holdings, Dames GP LLC, and Dmitry Balyasny by virtue of management and control relationships. The 1,360,391 figure consists of 1,217,534 shares held by Atlas Diversified Master Fund, Ltd. and 142,857 shares issuable upon exercise of warrants; the warrants are subject to a 9.99% Beneficial Ownership Limitation.
Verastem, Inc. filed a current report stating that it has posted an updated corporate presentation on its website. The presentation is dated May 7, 2026 and is furnished as Exhibit 99.1. This Form 8-K is presented under Regulation FD, providing investors with access to the same information.
Verastem, Inc. reports first-quarter 2026 results, showing its transition to a commercial-stage oncology company but also emphasizing substantial doubt about its ability to continue as a going concern over the next twelve months.
The company generated $18.7 million in net product revenue from AVMAPKI FAKZYNJA CO-PACK in the United States, compared with no revenue a year earlier. Operating expenses rose to $63.6 million, driven mainly by $38.2 million in research and development and $22.3 million in selling, general and administrative costs.
Verastem recorded a net loss of $36.6 million, an improvement from a $52.1 million loss in the prior-year quarter, helped by a $9.3 million non-cash gain from changes in warrant liability fair value. Cash, cash equivalents, restricted cash and investments totaled about $181.9 million as of March 31, 2026, but management’s assessment highlights continued operating losses, significant cash use and dependence on future financings or revenues, leading to the disclosed going concern uncertainty.
Verastem, Inc. President and CEO Dan Paterson reported an open-market sale of 806 shares of common stock at $5.82 per share. After the transaction, he directly holds 612,113 shares of Verastem common stock.
The filing explains that the sale was made to satisfy statutory withholding requirements arising from the vesting of restricted stock units, indicating it was a tax-related transaction tied to equity compensation rather than a discretionary reduction of his overall stake.
Verastem, Inc. is asking stockholders to vote at its 2026 annual meeting on May 21, 2026, in Needham, Massachusetts. Holders of 87,842,899 common shares as of March 24, 2026 may vote.
Stockholders will elect three Class II directors, including two incumbents and new nominee Michael P. Bailey, and vote on four other proposals. These include approval of an Amended and Restated 2021 Equity Incentive Plan adding 12,000,000 shares, and an Amended and Restated 2018 Employee Stock Purchase Plan adding 5,000,000 shares. Verastem estimates total potential dilution from existing equity plans and the new share pool at 18.1%.
Investors are also asked to ratify Ernst & Young LLP as auditor for 2026 and approve an advisory say‑on‑pay vote for named executive officers. The Board unanimously recommends voting in favor of all proposals.